Restoring the silenced Friedreich's ataxia gene through unconventional means

In a study published in Nature Cell Biology, scientists at St. Jude Children's Research Hospital have found an unconventional method to reactivate the silenced gene responsible for Friedreich's ataxia. Normally, genes are controlled by tightly packaged DNA, but researchers discovered that under certain conditions, this packaging behaves more like a thick fluid, allowing a specially designed chemical to bypass the packaging and activate the gene.

The protein frataxin, which is crucial in Friedreich's ataxia, is abnormally silenced due to the accumulation of repeated DNA sequences that attract methylation marks. These marks cause the protein HP1 to compact the DNA into dense condensates, effectively silencing the gene. The research team, led by Aseem Ansari, sought to disrupt this process using a synthetic gene regulator called SynGR1.

SynGR1 bound the repetitive DNA sequences and recruited the gene-activating protein BRD4 to the site. However, the team made an unexpected discovery: while the gene was being activated, the methylation marks that signal repression actually increased. This finding contradicted previous assumptions that histone modifications were simple "on" or "off" switches.

Despite the increased methylation marks, BRD4 could still enter the repressive environment created by HP1 condensates and bring along RNA polymerase II, the enzyme necessary for gene transcription. This allowed gene expression to continue within what would otherwise be a hostile environment. The researchers concluded that HP1 condensates could potentially be targeted to reactivate silenced genes, such as the frataxin gene in Friedreich's ataxia, or suppress abnormally active genes, like those involved in Huntington's disease.

However, they also cautioned that the complexity of histone modifications makes predicting outcomes challenging, emphasizing the importance of considering context in this biological phenomenon.